UA74362C2 - Фармацевтично активні похідні піролідину - Google Patents

Фармацевтично активні похідні піролідину

Info

Publication number
UA74362C2
UA74362C2 UA2002097675A UA200297675A UA74362C2 UA 74362 C2 UA74362 C2 UA 74362C2 UA 2002097675 A UA2002097675 A UA 2002097675A UA 200297675 A UA200297675 A UA 200297675A UA 74362 C2 UA74362 C2 UA 74362C2
Authority
UA
Ukraine
Prior art keywords
pyrrolidine derivatives
formula
group
present
compounds
Prior art date
Application number
UA2002097675A
Other languages
English (en)
Russian (ru)
Inventor
Серж Халазі
Маттіас Шварц
Маттиас Шварц
Анна Куаттропані
Анна Куаттропани
Рассел Томас
Ентоні Бакстер
Александер Шеер
Original Assignee
Еплайд Рісьорч Системз Ерс Холдінг Н.В.
Эплайд Рисерч Системз Эрс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еплайд Рісьорч Системз Ерс Холдінг Н.В., Эплайд Рисерч Системз Эрс Холдинг Н.В. filed Critical Еплайд Рісьорч Системз Ерс Холдінг Н.В.
Publication of UA74362C2 publication Critical patent/UA74362C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Цей винахід належить до похідних піролідину формули (І). Згадані сполуки призначені, головним чином, для використання як фармацевтично активних сполук. Зокрема, похідні піролідину формули (І) є придатними для лікування та/або запобігання передчасним пологам та дисменореї. Зокрема, цей винахід належить до похідних піролідину, які демонструють значну модуляторну здатність, зокрема антагоністичну активність щодо рецептора окситоцину. За варіантом, якому віддається більша перевага, згадані сполуки є придатними для лікування та/або запобігання хворобливим станом, які опосередковуються окситоцином, у тому числі передчасних пологів та дисменореї. Цей винахід додатково належить до нових похідних піролідину, а також до способів їх одержання, де Χ вибирають із групи, до складу якої входять CR6R7, NOR6, NNR6R7; А вибирають із групи, до складу якої входять -(С=O)-, -(С=O)-O-, -C(=NH)-, -(C=O)-NH-, (C=S)-NH, -SO2-, -SO2NH-, -СН2-, В або є групою –(C=O)-NR8R9, або являє собою гетероциклічний залишок, який має формулу (а), де Q - NR10, О або S; n - ціле число, яке вибирають з 0, 1 або 2; Y, Z та Е, разом із 2 атомами вуглецю, до яких вони приєднані, утворюють 5-6-членне арильне або гетероарильне кільце , (I) .(a)
UA2002097675A 2000-03-27 2001-03-20 Фармацевтично активні похідні піролідину UA74362C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106034 2000-03-27
PCT/EP2001/003171 WO2001072705A1 (en) 2000-03-27 2001-03-20 Pharmaceutically active pyrrolidine derivatives as bax inhibitors

Publications (1)

Publication Number Publication Date
UA74362C2 true UA74362C2 (uk) 2005-12-15

Family

ID=8168169

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002097675A UA74362C2 (uk) 2000-03-27 2001-03-20 Фармацевтично активні похідні піролідину

Country Status (33)

Country Link
US (2) US7211601B2 (uk)
EP (1) EP1268419B1 (uk)
JP (2) JP2003528854A (uk)
KR (1) KR100714585B1 (uk)
CN (1) CN1296354C (uk)
AR (1) AR029499A1 (uk)
AT (1) ATE330940T1 (uk)
AU (2) AU2001256209B2 (uk)
BG (1) BG107132A (uk)
BR (1) BR0109900A (uk)
CA (1) CA2401242A1 (uk)
CY (1) CY1105519T1 (uk)
CZ (1) CZ20023243A3 (uk)
DE (1) DE60120940T2 (uk)
DK (1) DK1268419T3 (uk)
EA (1) EA006424B1 (uk)
EE (1) EE200200555A (uk)
ES (1) ES2261404T3 (uk)
HK (1) HK1054031B (uk)
HR (1) HRP20020705A2 (uk)
HU (1) HUP0300994A2 (uk)
IL (1) IL151912A0 (uk)
MX (1) MXPA02009382A (uk)
NO (1) NO323969B1 (uk)
NZ (1) NZ521060A (uk)
PL (1) PL358001A1 (uk)
PT (1) PT1268419E (uk)
SI (1) SI1268419T1 (uk)
SK (1) SK13832002A3 (uk)
UA (1) UA74362C2 (uk)
WO (1) WO2001072705A1 (uk)
YU (1) YU73502A (uk)
ZA (1) ZA200206799B (uk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329899T1 (de) * 2000-03-27 2006-07-15 Applied Research Systems Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren
UA75145C2 (en) * 2001-06-18 2006-03-15 Applied Research Systems Pyrrolidine oxadiazole and thiadiazole derivatives, pharmaceutical composition based thereon, a method for producing thereof (variants)
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
JP4773335B2 (ja) * 2003-02-27 2011-09-14 メルク セローノ ソシエテ アノニム オキシトシンアンタゴニストとしてのピロリジン誘導体
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
DK1725526T3 (da) * 2004-02-26 2008-03-03 Serono Lab Fremgangsmåde til fremstilling af pyrrolidinoximer
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
JP2012512877A (ja) * 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
CN114621962B (zh) * 2022-03-21 2024-05-14 广西大学 花生AhBI-1基因VIGS沉默体系
TW202435864A (zh) 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用
CN117044622A (zh) * 2023-09-22 2023-11-14 贵州师范大学 一种无花瓣芥菜型油菜的选育方式

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL23907A (en) 1964-08-05 1971-05-26 Upjohn Co Lincomycin analogues and a process for their production
US3555007A (en) 1968-07-22 1971-01-12 Upjohn Co 7-deoxy-7-halo lincomycin d derivatives
US3674647A (en) 1970-10-07 1972-07-04 Upjohn Co Preparation of lincomycin analogues
ZA801424B (en) * 1979-03-12 1981-03-25 Warner Lambert Co Novel antibactrial amide compounds and process means for producing the same
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
GB9316162D0 (en) 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
CA2210138A1 (en) 1995-01-24 1996-08-01 Peter D. Williams Tocolytic oxytocin receptor antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
KR100633349B1 (ko) * 1998-07-14 2006-10-16 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제
CA2339018A1 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
CZ20012722A3 (cs) * 1999-01-27 2002-08-14 Ortho-Mcneil Pharmaceutical, Inc. Peptidylové heterocyklické ketony pouľitelné jako inhibitory typtasy
EP1158996A4 (en) * 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES
CN1362947A (zh) * 1999-03-15 2002-08-07 Axys药物公司 用作蛋白酶抑制剂的n－氰基甲基酰胺
US6333344B1 (en) * 1999-05-05 2001-12-25 Merck & Co. Prolines as antimicrobial agents
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
ATE329899T1 (de) * 2000-03-27 2006-07-15 Applied Research Systems Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren

Also Published As

Publication number Publication date
HUP0300994A2 (hu) 2003-08-28
HRP20020705A2 (en) 2004-12-31
PL358001A1 (en) 2004-08-09
DE60120940T2 (de) 2007-01-25
DK1268419T3 (da) 2006-10-02
CN1296354C (zh) 2007-01-24
JP5580364B2 (ja) 2014-08-27
ZA200206799B (en) 2003-08-26
KR100714585B1 (ko) 2007-05-07
ATE330940T1 (de) 2006-07-15
AR029499A1 (es) 2003-07-02
US7211601B2 (en) 2007-05-01
SI1268419T1 (sl) 2006-10-31
EE200200555A (et) 2004-06-15
KR20020095195A (ko) 2002-12-20
ES2261404T3 (es) 2006-11-16
EA006424B1 (ru) 2005-12-29
MXPA02009382A (es) 2003-01-28
CN1419541A (zh) 2003-05-21
CY1105519T1 (el) 2010-07-28
JP2012149098A (ja) 2012-08-09
HK1054031A1 (en) 2003-11-14
CZ20023243A3 (cs) 2003-01-15
BG107132A (bg) 2003-04-30
EP1268419A1 (en) 2003-01-02
US20080167318A1 (en) 2008-07-10
SK13832002A3 (sk) 2003-03-04
NO323969B1 (no) 2007-07-23
IL151912A0 (en) 2003-04-10
NO20024598L (no) 2002-11-25
EA200201026A1 (ru) 2003-02-27
YU73502A (sh) 2005-11-28
CA2401242A1 (en) 2001-10-04
DE60120940D1 (de) 2006-08-03
AU2001256209B2 (en) 2006-02-16
BR0109900A (pt) 2003-06-03
JP2003528854A (ja) 2003-09-30
US20030212012A1 (en) 2003-11-13
NZ521060A (en) 2004-05-28
EP1268419B1 (en) 2006-06-21
AU5620901A (en) 2001-10-08
HK1054031B (zh) 2007-05-04
PT1268419E (pt) 2006-08-31
NO20024598D0 (no) 2002-09-25
WO2001072705A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
UA74362C2 (uk) Фармацевтично активні похідні піролідину
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
NO20071703L (no) Kinazolinderivater
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
TW200732339A (en) Nitrogen-containing bicyclic heteroaryl compounds and methods of use
MY146279A (en) Compounds affecting glucokinase
JP2005509622A5 (uk)
EA200700099A1 (ru) Производные пиридина
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
TW200635918A (en) Pharmaceutical compounds
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
TW200640900A (en) 1-(2h)-isoquinolone derivative
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
DE60208178D1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
MX2012008147A (es) Derivados de pirrazolopiridina.
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
TW200616636A (en) Novel compounds
BG108424A (en) Pyrrolidineoxadiazole and pyrrolidinethiadiazole derivatives